{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T06:10:47Z","timestamp":1782627047808,"version":"3.54.5"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,7]]},"abstract":"<jats:p>Ibrutinib is reported effective in the management of refractory\/relapsed primary central nervous system lymphoma but it has adverse effects. Orelabrutinib has received its first approval for the treatment of refractory\/relapsed lymphoma either alone or with chemotherapy in China. The objectives of the retrospective study were to evaluate the efficacy and safety of treatment a combination of orelabrutinib (150\u2009mg\/day) and rituximab (250\u2009mg\/m<jats:sup>2<\/jats:sup> per week), <jats:italic toggle=\"yes\">versus<\/jats:italic> orelabrutinib alone (100\u2009mg twice a day) and ibrutinib alone (560\u2009mg\/day) among patients with refractory\/relapsed primary central nervous system lymphoma. Patients received 150\u2009mg\/day orelabrutinib with 250\u2009mg\/m<jats:sup>2<\/jats:sup> rituximab\/week (RO cohort, n = 105) or 100\u2009mg twice in a day orelabrutinib (OB cohort, n = 107) or 560\u2009mg\/day ibrutinib (IB cohort, n = 117) until intolerable toxicity. Patients of the OB cohort continue treatment(s) for longer time than those patients of the RO and the IB cohorts (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05 for both). Overall response rate (complete response + partial response) and disease control rates (complete response + partial response + no signs of progressive response) were higher for patients of the RO cohort than those of the IB cohort (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .0001 for both). The disease control rate was higher for patients of the OB cohort than those of the IB cohort (<jats:italic toggle=\"yes\">P<\/jats:italic> = .0062). The overall response rate was higher for patients of the RO cohort than those of the OB cohort (<jats:italic toggle=\"yes\">P<\/jats:italic> = .0188). Progression-free survival (from the initiation of disease treatment(s) to disease progression) of patients of the RO and OB cohorts were higher than those of the IB cohort (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .0001 for both). Overall survival (from the initiation of disease treatment(s) to death) of the patients of the IB cohort was fewer than those of the RO (<jats:italic toggle=\"yes\">P<\/jats:italic> = .0444) and the OB (<jats:italic toggle=\"yes\">P<\/jats:italic> = .0163) cohorts. Ibrutinib cause bleeding events, and orelabrutinib caused leukopenia, purpura diarrhea, fatigue, and drowsiness. Rituximab and ibrutinib cause fungal infections, atrial fibrillation, bacterial and viral infection(s), hypertension, and tumor lysis syndrome. A total of 150\u2009mg\/day oral orelabrutinib plus 250\u2009mg\/m<jats:sup>2<\/jats:sup> intravenous rituximab\/week is efficacious and safe for patients with refractory\/relapsed primary central nervous system lymphoma (Level of Evidence: IV; Technical Efficacy Stage: 5).<\/jats:p>","DOI":"10.1097\/md.0000000000033880","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T12:04:58Z","timestamp":1688731498000},"page":"e33880","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Orelabrutinib versus ibrutinib for patients with refractory\/relapsed primary central nervous system lymphoma: An efficacy and safety analysis"],"prefix":"10.1097","volume":"102","author":[{"given":"Lijiao","family":"Qiao","sequence":"first","affiliation":[{"name":"Department of Oncology, the General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, the General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3601-2348","authenticated-orcid":false,"given":"Chunzhou","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, the General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","first-page":"1","article-title":"Efficacy and safety of ibrutinib in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis.","volume":"707285","author":"Lv","year":"2021","journal-title":"Front Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS Lymphoma.","volume":"35","author":"Grommes","year":"2017","journal-title":"J Clin Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary.","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.17811","article-title":"Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?.","volume":"196","author":"Morin","year":"2022","journal-title":"Br J Haematol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/17474086.2019.1643232","article-title":"Aggressive non-hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.","volume":"12","author":"Santambrogio","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/neuonc\/noy193","article-title":"Introduction of novel agents in the treatment of primary CNS lymphoma.","volume":"21","author":"Grommes","year":"2019","journal-title":"Neuro Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"901797","DOI":"10.3389\/fonc.2022.901797","article-title":"Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: a retrospective analysis of case series.","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"R8-20250504","first-page":"CD009355","article-title":"Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).","volume":"11","author":"Bergner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/neuonc\/now033","article-title":"Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC network.","volume":"18","author":"Langner-Lemercier","year":"2016","journal-title":"Neuro Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1158\/2159-8290.CD-17-0714","article-title":"Spotlight on ibrutinib in PCNSL: s another feather to its cap.","volume":"7","author":"Lakshmanan","year":"2017","journal-title":"Cancer Discov"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies.","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"issue":"7 Spec No","key":"R12-20250504","first-page":"SP226","article-title":"Second-generation BTK inhibitors hit the treatment bullseye with fewer off-target effects.","volume":"26","author":"Shaw","year":"2020","journal-title":"Am J Manag Care"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: first approval.","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s10637-022-01219-5","article-title":"Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.","volume":"40","author":"Wu","year":"2022","journal-title":"Invest New Drugs"},{"key":"R15-20250504","first-page":"101682","article-title":"Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study.","volume":"52","author":"Cao","year":"2022","journal-title":"E Clin Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.omto.2021.03.015","article-title":"Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.","volume":"21","author":"Yu","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"289","DOI":"10.21147\/j.issn.1000-9604.2021.03.01","article-title":"Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version).","volume":"33","author":"Zhu","year":"2021","journal-title":"Chin J Cancer Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"R20-20250504","first-page":"755","article-title":"Safety and efficacy of orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase ii study.","volume":"134","author":"Song","year":"2020","journal-title":"Blood"},{"key":"R21-20250504","first-page":"1","article-title":"Lugano classification: response evaluation criteria for positron emission tomography\/computed tomography in lymphoma follow-up.","volume":"181","author":"Ragheb","year":"2020","journal-title":"Egypt J Radiol Nucl Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:01:43Z","timestamp":1746324103000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":20,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033880","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}